Emerging Trends in Pharma and Biotech
126 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Bioassociate
Scoop.it!

Biotech & Pharma 2013 Licensing & Partnering Activity Review: Diminishing Upfronts, Increasing Platform Licenses Indicate Stronger Risk Aversion among Big Pharma

Biotech & Pharma 2013 Licensing & Partnering Activity Review: Diminishing Upfronts, Increasing Platform Licenses Indicate Stronger Risk Aversion among Big Pharma | Emerging Trends in Pharma and Biotech | Scoop.it
more...
No comment yet.
Rescooped by Bioassociate from PharmaChange
Scoop.it!

Merck Serono Israel incubator nurtures early stage projects

Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.

Via Aleksandra Misiorowska
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

2013 Pharma M&A Review: Earlier-Stage Pipelines, Lower Premiums, and Cancer

2013 Pharma M&A Review: Earlier-Stage Pipelines, Lower Premiums, and Cancer | Emerging Trends in Pharma and Biotech | Scoop.it
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Pharma R&D in China: The Role of the "Hai Gui" - the returnees

Pharma R&D in China: The Role of the "Hai Gui" - the returnees | Emerging Trends in Pharma and Biotech | Scoop.it
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Bioassociate Industry Blog: Why the Pharma Industry No Longer Warrants Public Trust: Reasons for Extortionate Big Pharma Drug Prices, and What Governments Are Doing to Contain Them

Bioassociate Industry Blog: Why the Pharma Industry No Longer Warrants Public Trust: Reasons for Extortionate Big Pharma Drug Prices, and What Governments Are Doing to Contain Them | Emerging Trends in Pharma and Biotech | Scoop.it
more...
No comment yet.
Rescooped by Bioassociate from Entrepreneurship, R&D, Maketing, Innovation
Scoop.it!

Bio-brand your way through the valley of death and beyond

Bio-brand your way through the valley of death and beyond | Emerging Trends in Pharma and Biotech | Scoop.it
Bio-brand your way through the valley of death and beyond - Articles If there is any truth biotech founders may rely on, it is that they will be Googled by potential investors, says Bioassociate's Julia Skripka-Serry.

Via Ari Massoudi
more...
Ari Massoudi's curator insight, May 25, 2013 7:03 AM

If there is any truth biotech founders may rely on, it is that they will be Googled by potential investors, says Bioassociate's Julia Skripka-Serry. Building a bio-brand from day zero can become the defining factor in a biotech's investability and survival.

Scooped by Bioassociate
Scoop.it!

RedHill Biopharma Ltd: Initiation of Coverage Bioassociate Innovative Life Science Consulting | Biotech Consulting Israel

RedHill Biopharma Ltd: Initiation of Coverage Bioassociate Innovative Life Science Consulting | Biotech Consulting Israel | Emerging Trends in Pharma and Biotech | Scoop.it

RedHill Biopharma Ltd. is a publically traded pharmaceutical company focused on the development of late clinical-stage drug candidates, based on improved formulations and combinations of existing drugs. The Company is advancing the clinical development of its programs through the FDA’s 505(b)(2) regulatory pathway, which allows lowered development risks and costs, along with faster time to market. 

RedHill is currently advancing 6 clinical programs; two of which are expected to be submitted for regulatory review by the FDA during 2013, and two are entering pivotal clinical studies. The Company aims to find strategic partners for the marketing and distribution of its products.

more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Bioassociate Industry Blog

Bioassociate Industry Blog | Emerging Trends in Pharma and Biotech | Scoop.it
Bioassociate's insight:

The Bioassociate Industry Blog covers the latest analysts reports of promising biotechs and the latest trends in the Pharma world. 

more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Scripintelligence - NAS in 2012: launch tally is century's best

Scripintelligence - NAS in 2012: launch tally is century's best | Emerging Trends in Pharma and Biotech | Scoop.it
R&D in the international pharmaceutical industry appears in ruder health than some might think.
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Bioassociate Industry Blog: FDA Breakthrough Designation and what it means for Pharma | Entrepreneurship, R&D, Maketing, Innovation

Bioassociate Industry Blog: FDA Breakthrough Designation and what it means for Pharma | Entrepreneurship, R&D, Maketing, Innovation | Emerging Trends in Pharma and Biotech | Scoop.it
Ari Massoudi's insight: FDA Breakthrough Designation and what it means for Pharma (RT @arimassoudi: Bioassociate Industry Blog: FDA Breakthrough Designation and what it means for Pharma | http://t.co/XzXM1k9NrE...
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

The great neuro-pipeline ‘brain drain’ (and why Big Pharma hasn’t given up on CNS disorders)

The great neuro-pipeline ‘brain drain’ (and why Big Pharma hasn’t given up on CNS disorders) | Emerging Trends in Pharma and Biotech | Scoop.it
Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Yet they have become as much a vice as a potential virtue.
Bioassociate's insight:

Bioassociate is on the cover of this fall's Drug Discovery World with an article discussing why Big Pharma no longer risks developing brain drugs 

more...
Ari Massoudi's curator insight, January 2, 2014 5:26 AM

Bioassociate
Life science, biotech and pharma consulting with a twist from the heart of the world's Start-up Nation - Israel. Follow us for the coolest bio-developments!
http://www.bioassociate.com 

Scooped by Bioassociate
Scoop.it!

2013 Biotech & Pharma IPO Review – Most Popular Therapeutic trends, Trending Clinical Stages and post-IPO Winners & Losers

2013 Biotech & Pharma IPO Review – Most Popular Therapeutic trends, Trending Clinical Stages and post-IPO Winners & Losers | Emerging Trends in Pharma and Biotech | Scoop.it
Bioassociate's insight:

Biotech continues to outperform other sectors, even as venture capital wallets are shrinking. An unprecedented 46 biotech and pharma companies went public this year, in what has become an IPO frenzy of over a decade. For the most part, thenewly public companies are developing drugs targeting cancer, infectious disease (especially antibiotic-resistant bacteria) and brain disorders. But some new therapeutic areas which are gaining popularity might surprise you. Check out our latest blog post to find out which diseases are "popular" in the pharma world, and who, so far, are the biggest gainers and losers of this year's IPO craze

more...
Bioassociate's curator insight, December 14, 2013 10:34 AM

Biotech continues to outperform other sectors, even as venture capital wallets are shrinking. An unprecedented 46 biotech and pharma companies went public this year, in what has become an IPO frenzy of over a decade. For the most part, thenewly public companies are developing drugs targeting cancer, infectious disease (especially antibiotic-resistant bacteria) and brain disorders. But some new therapeutic areas which are gaining popularity might surprise you. Check out our latest blog post to find out which diseases are "popular" in the pharma world, and who, so far, are the biggest gainers and losers of this year's IPO craze

Scooped by Bioassociate
Scoop.it!

The great neuro-pipeline ‘brain drain’ (and why Big Pharma hasn’t given up on CNS disorders)

The great neuro-pipeline ‘brain drain’ (and why Big Pharma hasn’t given up on CNS disorders) | Emerging Trends in Pharma and Biotech | Scoop.it
Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Yet they have become as much a vice as a potential virtue.
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Bioassociate Industry Blog: Upcoming FDA drug approval decision (PDUFA): Otsuka Pharmaceuticals - Samsca (tolvaptan)

Bioassociate Industry Blog: Upcoming FDA drug approval decision (PDUFA): Otsuka Pharmaceuticals - Samsca (tolvaptan) | Emerging Trends in Pharma and Biotech | Scoop.it
Otsuka is a diversified pharmaceutical company based in Tokyo and Osaka, Japan. It is currently the second largest pharma player in Japan, and, despite its predominantly nutraceutical focus, Otsuka is actively looking to specialize in innovative pharmaceuticals targeting central nervous system disorders and oncology. 
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Grim Near-Term Prospects For Zogenix

Grim Near-Term Prospects For Zogenix | Emerging Trends in Pharma and Biotech | Scoop.it
Zogenix (ZGNX) is still awaiting a response from the FDA for the approval of Zohydro ER, after the agency has delayed the scheduled approval decision date of March 1st.
more...
No comment yet.
Scooped by Bioassociate
Scoop.it!

Bioassociate Industry Blog: FDA Breakthrough Designation and what it means for Pharma

Bioassociate Industry Blog: FDA Breakthrough Designation and what it means for Pharma | Emerging Trends in Pharma and Biotech | Scoop.it

Drugs in Phase I clinical trials may be finding themselves bumped straight up to market after a new "Breakthrough Therapy Designation" was introduced by the FDA as part of the 2012 FDA Safety and Innovation Act (FDASIA) on July 9 of 2012. 

more...
No comment yet.
Rescooped by Bioassociate from Pharmaceuticals and The World
Scoop.it!

Bacteria used to clean pharmaceuticals from sewage - DigitalJournal.com

Bacteria used to clean pharmaceuticals from sewage - DigitalJournal.com | Emerging Trends in Pharma and Biotech | Scoop.it
DigitalJournal.com
Bacteria used to clean pharmaceuticals from sewage
DigitalJournal.com
As more and more sophisticated pharmaceutical products are used the risk of chemicals remaining in the water supply becomes higher (according to the U.S.

Via Jeff Stockman
more...
Jeff Stockman's curator insight, March 3, 2013 10:38 PM

we take drugs so much that the effects dont end with us

Rescooped by Bioassociate from Entrepreneurship, R&D, Maketing, Innovation
Scoop.it!

Bioassociate Industry Blog: KaloBios Pharmaceuticals, Inc.: Bioassociate Initiation of Coverage

Bioassociate Industry Blog: KaloBios Pharmaceuticals, Inc.: Bioassociate Initiation of Coverage | Emerging Trends in Pharma and Biotech | Scoop.it

Via Ari Massoudi
more...
Ari Massoudi's curator insight, March 5, 2013 7:33 AM

KaloBios Pharmaceuticals, Inc.: Bioassociate Initiation of Coverage

Scooped by Bioassociate
Scoop.it!

Biotech Billionaire's Latest Drug Bet Implodes - Forbes

Biotech Billionaire's Latest Drug Bet Implodes - Forbes | Emerging Trends in Pharma and Biotech | Scoop.it
Proactive Investors USA & Canada
Biotech Billionaire's Latest Drug Bet Implodes
Forbes
Biotech investor R.J.
more...
No comment yet.